



Scholars Research Library

Der Pharmacia Lettre, 2010, 2(4): 126-131
(<http://scholarsresearchlibrary.com/archive.html>)



An efficient synthesis of 1, 2, 4-triazine derivatives and their in vitro antimicrobial activity

Bhaskar S. Dawane*, Shuddhodan N.Kadam, Baseer M.Shaikh.

Organic Research Laboratory, Department of Chemistry
¹Yeshwant Mahavidyalaya, Nanded-431602 (M.S) India

Abstract

A simple and efficient synthesis of 1, 2, 4- triazine derivatives is described by the condensation of substituted 4-(2-chloro-quinoline-3yl methylene)-2-[phenyl-4H-oxazol-5-one and phenyl hydrazine an equimolar sodium acetate and acetic acid as a solvent. The newly synthesized compounds were evaluated for their antimicrobial activity.

Keywords: Substituted 4-(2-chloro-quinoline-3yl methylene)-2-[phenyl-4H-oxazol-5-one, phenyl hydrazine, Triazine derivatives, antimicrobial activity.

INTRODUCTION

Triazine derivatives have occupied a unique position in medicinal chemistry. Triazine derivatives have attracted considerable pharmaceutical interest due to their antitumor [1-5], anticonvulsant⁶ and antileukemic [7, 8] activities and cytotoxic effects [9]

Triazine has been used to form many types of functional groups other than amines and heterocycles and used as protecting groups in natural product synthesis. Thus, they are reactive groups, which are adaptable to different synthetic transformations.

Among the compound having good antimicrobial properties, s-triazine derivatives constitute an important class of compounds possessing diverse pharmacological activities including broadly active triazine compounds. The synthetic strategy of the compounds is outlined in the scheme-1. Synthesis of some new substituted of 1, 2, 4- triazine derivatives was carried out by the condensation of Substituted 4-(2-chloro-quinoline-3yl methylene)-2-[phenyl-4H-oxazol-5-one and phenyl hydrazine in glacial acetic acid as a solvent. (Table-1).

MATERIAL AND METHOD

Melting points were uncorrected and determined in an open capillary tube. IR spectra were recorded on FTIR Shimadzu spectrometer. ^1H NMR spectra were recorded in $\text{DMSO-}d_6$ on Avance 300 MHz spectrometer using TMS as an internal standard. The mass spectra were recorded on EI-Shimadzu-GC-MS spectrometer. Elemental analyses were performed on a Carlo Erba 106 Perkin-Elmer model 240 analyzer.

General procedure for the synthesis of 1, 2, 4-triazine derivatives 3(a-j)

Substituted 4-(2-chloro-quinoline-3-yl methylene)-2-[phenyl-4H-oxazol-5-one **1** (1 mMol) was taken in 100 ml RBF and 1.08 gm of phenyl hydrazine **2** was also added to 10-15 ml of glacial acetic acid and 0.2 gm of sodium acetate and mixture is refluxed for about 5 hrs. finally The resultant solid was filtered, washed with ice cold water (50 ml) followed by cool ethanol (10 ml) to give the corresponding product.

Spectroscopic data of selected compounds

5-((2-Chloro-6-methylquinoline-3-yl)methylene)-2,3diphenyl-1,2-dihydro-1,2,4-triazine-6(5H)-one.(3a):

IR (KBr): 3049, 3325, 1716, 1653 cm^{-1} ; ^1H NMR ($\text{DMSO-}d_6$, 300 MHz): δ 1.3 (s, 3H, $-\text{CH}_3$), δ 8.78 (d, 1H, Ar-H), δ 8.68 (d, 1H, Ar-H), δ 6.95-8.35 (m, 14H, Ar-H), δ 7.0 (s, 1H, $-\text{NH}$) ppm; EIMS (m/z): 442 (M^+); Anal. Calcd. For $\text{C}_{26}\text{H}_{19}\text{ON}_4\text{Cl}$: C, 71.15, H, 4.36; N, 12.77%. Found: C, 71.00; H, 4.30; N, 12.65%

5-((6-Bromo-2-Chloroquinoline-3-yl)methylene)-2,3diphenyl-1,2-dihydro-1,2,4-triazine-6(5H)-one.(3b):


:IR (KBr): 3045, 3322, 1710, 1645 cm^{-1} ; ^1H NMR ($\text{DMSO-}d_6$, 300 MHz): δ 8.78 (d, 1H, Ar-H), δ 6.95-8.35 (m, 14H, Ar-H), δ 7.0 (s, 1H, $-\text{NH}$) ppm; EIMS (m/z): 504 (M^+); Anal. Calcd. For $\text{C}_{25}\text{H}_{16}\text{ON}_4\text{BrCl}$: C, 59.60, H, 5.20; N, 11.12%. Found: C, 59.30; H, 5.10; N, 10.90%

5-((2-Chloro-6-methoxyquinoline-3-yl)methylene)-2,3diphenyl-1,2-dihydro-1,2,4-triazine-6(5H)-one.(3c):

:IR (KBr): 3040, 3335, 1726, 1640 cm^{-1} ; ^1H NMR ($\text{DMSO-}d_6$, 300 MHz): δ 2.01 (s, 3H, $-\text{OCH}_3$) δ 8.78 (d, 1H, Ar-H), δ 6.95-8.35 (m, 14H, Ar-H), δ 7.0 (s, 1H, $-\text{NH}$) ppm; EIMS (m/z): 455 (M^+); Anal. Calcd. For $\text{C}_{26}\text{H}_{19}\text{O}_2\text{N}_4\text{Cl}$: C, 68.6, H, 4.21; N, 12.32%. Found: C, 67.95; H, 4.10; N, 12.10%


RESULTS AND DISCUSSION

As part of our research programme, and in continuation of our work on the development of environmentally friendly methodologies for the preparation of biologically active compounds [10-13], herein we report an efficient synthesis of substituted 1, 2, 4-triazine derivatives. The condensation of substituted 4-(2-chloro-quinoline-3-yl methylene)-2-[phenyl-4H-oxazol-5-one **1**, phenyl hydrazine **2**, sodium acetate using glacial acetic acid as reaction solvent to afford the corresponding product **3(a-j)** (Scheme-1) in good yield. The newly synthesized compounds were evaluated for their antibacterial and antifungal activity.



Scheme-1: Synthesis of substituted 1, 2, 4-triazene derivatives 3(a-j)

The formation of the products was proceeding through the attack of phenyl hydrazine 2 on the carbonyl carbon of substituted 4-(2-chloro-quinoline-3-yl methylene)-2-[phenyl-4H-oxazol-5-one]. The formation of substituted 1, 2, 4-triazene derivatives involved the condensation of 1:1 molar ratio of substituted 1 and 2. However, The newly synthesized compounds confirmed by the spectral analysis and were evaluated for their antibacterial and antifungal activity.



Mechanism of formation of substituted 1, 2, 4-triazine derivatives 3(a-j).

Table-1: Physical data substituted 1, 2, 4-triazine derivatives 3(a-j)

Entry	Product	R	Yield (%)	M.P. (°C)
1	3a	CH ₃	83	205
2	3b	Br	85	195
3	3c	OCH ₃	79	185
4	3d	Cl	82	210
5	3e	NO ₂	70	205
6	3f	H	84	155
7	3g	I	86	166
8	3h	F	80	163

The antimicrobial activities of the synthesized compounds **3(a-j)** were determined by agar well diffusion method [14]. The compounds were evaluated for antibacterial activity against

Escherichia coli, *Salmonella typhi*, *Staphylococcus aureus* and *Bacillus subtilis*. The antifungal activity was evaluated against *Aspergillus niger*, *Aspergillus flavus*, and *Penicillium chrysogenum* were procured from Institute of Microbial technology (IMTech), Chandigarh, India. The antibiotic penicillin (25µg/mL) and nystatin (25µg/mL) was used as reference drug for antibacterial and antifungal activity, respectively. Dimethyl sulphoxide (1%, DMSO) was used a control with out compound.

The results of antimicrobial data are summarized in Table-2. In comparison with standard antibacterial penicillin, compounds **3b**, **3f**, found to be active against *E. coli*. Compounds **3c**, **3f**, were also found to be active against *S. aureus*. Compounds, **3b**, **3c**, **3g** showed good activity comparatively active against *B. subtilis*. As compared with standard antibacterial compounds **3a**, **3d**, **3e**, **3f**, **3g**, **3h** were observed as active against *S. typhi*. On the other hand, compound **3a**, **3c**, **3f**, **3g**, **3h** were found to be reduced growth activity against *A. niger*. Compounds **3d**, **3f** and **3h** were observed no fungal growth against *A. flavus*. Compounds **3a**, **3c**, **3e**, **3g**, **3h** found to be reduced growth activity against *P. chrysogenum*.

Table-2: The antimicrobial data of the synthesized substituted 1,2,4- triazine derivatives 3(a-j)

Product	Bacteria (Zone of inhibition in mm)				Fungi (Growth)		
	Ec	St	Sa	Bs	An	Af	Pc
3a	08	12	--	11	RD	+ve	RD
3b	11	10	09	10	+ve	RD	-ve
3c	10	08	13	10	RD	+ve	RD
3d	06	10	12	08	+ve	-ve	+ve
3e	11	13	10	10	+ve	RD	RD
3f	13	12	13	09	RD	-ve	-ve
3g	10	14	07	12	RD	RD	RD
3h	08	10	12	06	RD	-ve	RD
Penicillin	16	15	18	14	NA	NA	NA
Nystatin	NA	NA	NA	NA	-ve	-ve	-ve

Ec-*Escherichia coli*; St-*Salmonella typhi*; Sa-*Staphylococcus aureus*; Bs-*Bacillus subtilis*; An-*Aspergillus niger*; Af-*Aspergillus flavus*; Pc-*Penicillium chrysogenum*; -ve-No growth; +ve-Growth of fungi; RD-Reduced growth; NA-Not Applicable

CONCLUSION

In summary, we have described a simple method for the synthesis of 2-[4-(substituted -phenyl)-thiazol-2-yl]-5-(2-substituted quinolin-3-yl-methylene) 3-phenyl-2,5-dihydro-1H-[1,2,4]-triazine-6-one. The newly synthesized compounds were confirmed by the spectral analysis and further evaluated for their antimicrobial activity. The antibacterial and antifungal activity revealed that most of the compounds showed moderate to good activity. The substitution of presence of halo groups in positions emerged as active in both antibacterial and antifungal screening

Acknowledgements

One of the authors (BSD) is sincerely thankful to University Grant Commission, New Delhi for Post Doctoral Research Award (F. 30-1/2009, SA-II). Authors gratefully acknowledge to Principal, Yeshwant Mahavidyalaya, Nanded for providing laboratory facilities and IICT Hyderabad for spectral analysis.

REFERENCES

- [1] Gibson NW, Erickson LC, Hickman JA. *Cancer Res* **1984**, *44*, 1767.
- [2] Pilch DS, Kirolos MA, Liu X, Plum GE, Breslauer KJ. *Berenil Biochem.* **1995**, *34*, 9962.
- [3] Jean-Claude BJ, Mustafa A, Damian Z, Marte Ji, Vasilescu DE, Yen R., Chan TH, Leyland-Jones B. *Biochem. Pharmacol.* **1999**, *57*, 753.
- [4] Smith RH Jr, Scudiero DA, Michejda CJ. *J. Med. Chem.* **1990**, *33*, 2579,
- [5] Unsalan S, Rollas S. *Indian J. Chem. Sec. B-Org. Chem. Inc. Med. Chem.* **2007**, *46B*, 185.
- [6] Kumar A, Mukerjee SK, Bhattacharya SK. *Pharmazie* **1983**, *38*, 66.
- [7] Katsoulas A, Rachid Z, Brahim F, McNamee J, Jean-Claude BJ.. *Leukemia Res.* **2005**, *29*, 693.
- [8] Seiter K, Liu D, Loughran T, Siddiqui A, Baskind P, Ahmed T. *J. Clin. Oncol* **2002**, *20(15)*, 3249.
- [9] Manolov I, Machulla HJ, Momekov G. *Pharmazie* **2006**, *61(6)*, 511.
- [10] Kamble VT, Dawane BS, Chavan SA, Bhosale RB, *Aust. J. Chem.*, **2007**, *60*, 302.
- [11] Dawane. BS, Konda SG, Shaikh BM, Bhosle RB, *Acta Pharm.*, **2009**, *59*, 473.
- [12] Dawane BS, Konda SG, Shaikh BM, Mandawad GG. *Eur. J. Med. Chem*, **2010**, *45*, 357.
- [13] Dawane BS, Shaikh BM, Kamble VT, Konda SG, *Green Chemistry Letters and Reviews (in press)* 10.1080/17518251003709506.
- [14] Shrinivasan D, Sangeetha N, Suresh T, Lakshmanaperumalsamy P. *J. Ethnopharmacol*, **2001**, *74*, 217.